The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury - a Promising Drug to Address Post-Stroke Spasticity

Abstract

MPH-220 is a new-generation muscle relaxant targeting fast skeletal muscle myosin-2, while avoiding neurological, cardiac and respiratory adverse effects. MPH-220 is pharmacologically safe (non-toxic, non-mutagenic), and accumulates in skeletal muscles while its appearance in other tissues - including heart, esophageal and diaphragm samples - is minuscule and temporary. Its high metabolic stability combined with the accumulation in target tissues enables MPH-220 to reduce muscle force in rat hindleg by 50% after oral administration in an FDA-approved pharmacological formulation, which effect is maintained for more than 10 hours.